Skórski, Tomasz ; Nieborowska-Skórska, Małgorzata ; Szczylik, Cezary ; Calabretta, Bruno
Antisense Oligodeoxynucleotides: from the Bench to the Patient
Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS
In recent years, the antisense strategy for cancer therapy has progressed from in vitro culturestudies, to investigations in animal models, and now to clinical studies. We describe here thecurrent state of progress toward gene-directed antisense-based cancer therapy targetingBCR/ABL oncogene, primarily from the viewpoint of initial proof-of-concepts studies in animalmodels of human leukemias and phase I clinical investigations.
Biotechnologia, vol.35, 4 (1996)-.
0860-7796 ; oai:rcin.org.pl:146559 ; IChB B-31
Library of Institute of Bioorganic Chemistry PAS
Creative Commons Attribution BY-SA 4.0 license
Institute of Bioorganic Chemistry of the Polish Academy of Science
Institute of Bioorganic Chemistry of the Polish Academy of Science
Nov 9, 2020
Nov 9, 2020
33
https://rcin.org.pl/ichb/publication/182229
Edition name | Date |
---|---|
Antisense Oligodeoxynucleotides: from the Bench to the Patient | Nov 9, 2020 |
Skórski, Tomasz Nieborowska-Skórska, Małgorzata
Borkowska, Bożenna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Ratajczak, Mariusz Z. Skórski, Tomasz Białek, Andrzej